Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7702341 | 0.77 | ADORA2A (0.33) | GRM4 | |
| SCHEMBL30596252 | 0.77 | GRM4 (0.30) | GRM4 | |
| SCHEMBL16516791 | 0.77 | GRM4 (0.30) | GRM4 | |
| SCHEMBL19493600 | 0.73 | MAPK1 (0.37) | — | |
| SCHEMBL24168878 | 0.72 | — | — | |
| SCHEMBL30228553 | 0.72 | — | — | |
| SCHEMBL30365321 | 0.69 | GAA (0.34) | GRM4 | |
| SCHEMBL3775694 | 0.69 | GAA (0.34) | GRM4 | |
| SCHEMBL21055463 | 0.65 | GABRP (0.36) | GRM4 | |
| SCHEMBL30056844 | 0.65 | GABRP (0.36) | GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9546168-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160311819-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160311819-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-27 | — | — | US | disclosed |
| EP-3082810-A1 | ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015094929-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015094929-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311819-A1 | ERK INHIBITORS | MAPK1, MAPK10, MAPK3 | GRM4 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.